Bai et al. (2016) identified activation of aggressive oncogenic pathways such as the MYC or RTK-RAS-PI3K signaling pathways as well as important epigenetic pathways evident in the progression of IDH1-mutant gliomas [128]. This evidence concerns the gene IDH1 and central nervous system cancer.